240 related articles for article (PubMed ID: 8727804)
1. Diagnosis and treatment of superficial bladder cancer: an update.
Crawford ED
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):1-9. PubMed ID: 8727804
[TBL] [Abstract][Full Text] [Related]
2. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
Huben RP
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
[TBL] [Abstract][Full Text] [Related]
3. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
4. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy for superficial bladder cancer.
Baselli EC; Greenberg RE
Oncology (Williston Park); 2001 Jan; 15(1):85-8; discussion 88-91. PubMed ID: 11271984
[TBL] [Abstract][Full Text] [Related]
6. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
[TBL] [Abstract][Full Text] [Related]
8. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder.
van der Heijden AG; Kiemeney LA; Gofrit ON; Nativ O; Sidi A; Leib Z; Colombo R; Naspro R; Pavone M; Baniel J; Hasner F; Witjes JA
Eur Urol; 2004 Jul; 46(1):65-71; discussion 71-2. PubMed ID: 15183549
[TBL] [Abstract][Full Text] [Related]
9. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
10. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
12. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
13. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
14. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
15. Bladder cancer.
Gwynn ES; Clark PE
Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241
[TBL] [Abstract][Full Text] [Related]
16. Therapy of superficial bladder cancer.
Nseyo UO; Lamm DL
Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
[TBL] [Abstract][Full Text] [Related]
17. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
18. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
19. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
